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Genetically engineered mouse models (GEMMs) of cancer are increas-
ingly being used to assess putative driver mutations identified by
large-scale sequencing of human cancer genomes. To accurately
interpret experiments that introduce additional mutations, an under-
standing of the somatic genetic profile and evolution of GEMM tumors
is necessary. Here, we performed whole-exome sequencing of tumors
from three GEMMs of lung adenocarcinoma driven by mutant
epidermal growth factor receptor (EGFR), mutant Kirsten rat sarcoma
viral oncogene homolog (Kras), or overexpression ofMYC proto-
oncogene. Tumors from EGFR- and Kras-driven models exhibited, re-
spectively, 0.02 and 0.07 nonsynonymous mutations per megabase, a
dramatically lower average mutational frequency than observed in
human lung adenocarcinomas. Tumors from models driven by strong
cancer drivers (mutant EGFR and Kras) harbored few mutations in
known cancer genes, whereas tumors driven by MYC, a weaker initi-
ating oncogene in themurine lung, acquired recurrent clonal oncogenic
Kras mutations. In addition, although EGFR- and Kras-driven models
both exhibited recurrent whole-chromosome DNA copy number alter-
ations, the specific chromosomes altered by gain or loss were different
in each model. These data demonstrate that GEMM tumors exhibit
relatively simple somatic genotypes compared with human cancers
of a similar type, making these autochthonous model systems useful
for additive engineering approaches to assess the potential of novel
mutations on tumorigenesis, cancer progression, and drug sensitivity.
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Lung cancer remains the leading cause of cancer death worldwide,estimated to have caused 158,000 deaths in the United States in
2015 (seer.cancer.gov). Lung adenocarcinoma is the most common
form of lung cancer, in both smokers and nonsmokers. Tobacco
mutagens cause a high mutation frequency in the somatic genomes of
smoking-associated tumors, complicating identification of the genetic
drivers of tumor progression (1, 2). An increasing number of so-
matic alterations that can be targeted by existing drugs or drug
candidates have been identified in lung adenocarcinoma, and
several of these agents have demonstrated efficacy in patients (3).
Kirsten rat sarcoma viral oncogene homolog (KRAS) and epider-
mal growth factor receptor (EGFR) are the most frequently mutated
oncogenes in human lung adenocarcinoma (1, 2, 4, 5). KRAS mu-
tations are associated with a strong history of cigarette smoking,
whereas EGFR mutations are the most frequent oncogene alterat-
ions in lung cancers from never-smokers (6). Our groups and others
have generated genetically engineered mouse models (GEMMs) of
EGFR- and Kras-mutant lung adenocarcinoma (7–10). These models
recapitulate key features of the human disease, including histo-
logic architecture and response and resistance to conventional and
targeted therapies (11, 12). Although individual mice develop mul-
tifocal disease, only a subset of the primary Kras tumors progress to
metastatic disease. A distinct gene expression signature has been
shown to distinguish metastatic from nonmetastatic primary tumors
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in a KrasG12D-driven GEMM, suggesting that acquired genetic or
epigenetic alterations underlie metastatic progression (13).
Somatic genome evolution in tumors produced in GEMMs re-
mains incompletely characterized. Several studies have described
the spectrum of acquired DNA copy number alterations in murine
models (14–20). Although these studies reached varying conclu-
sions, it appears that somatic alterations in DNA copy number,
especially changes in copy number of certain whole chromosomes,
are a common somatic event during tumor evolution in GEMMs.
We also recently studied a GEMM of small cell lung cancer using
exome and whole-genome sequencing. In this model, which
is initiated by mutation of the p53 and retinoblastoma tumor
suppressors, we identified recurrent alterations in the PTEN/PI3K
pathway, in addition to previously identified focal DNA amplifi-
cations targeting theMycl1 oncogene (21–23). Together, these studies
suggest that, similar to human cancers, GEMM tumors can undergo
extensive genome remodeling during tumor progression and that a
subset of these acquired events contributes to cancer progression.
The mutational landscape of carcinogen-induced murine lung
adenocarcinomas was also recently described and compared with
that in tumors initiated by expression of an oncogenic Kras allele
(24). Not surprisingly, single nucleotide mutations, including Kras
mutations, were more frequently observed in carcinogen-induced
tumors. In contrast, secondary DNA copy number alterations were
more prevalent in tumors arising in genetically engineered mice.
This finding further suggests that the path of somatic alteration and
selection during tumor progression depends on the specific events
that initiate tumorigenesis. As previously described, the carcinogen-
treated tumors acquired clonal oncogenic Kras mutations. How-
ever, it remains unknown whether murine lung adenocarcinomas
initiated by other oncogenic drivers, or those harboring combined
loss of the tumor suppressor p53, acquire similar or distinct patterns
of somatic alteration during tumor evolution and progression.
Here, we describe the somatic evolution of a panel of tumors and
tumor-derived cell lines derived from GEMMs of lung adenocar-
cinoma initiated by Kras, EGFR, and MYC (10, 25–27).
Results
Mouse Models of Lung Adenocarcinoma Acquire Few Somatic Point
Mutations. We generated a panel of tumor specimens and tumor
cell lines from GEMMs of EGFR-, KRAS-, andMYC-mutant lung
adenocarcinomas (Fig. 1). We performed whole-exome sequenc-
ing on tumors and cell lines from these models to profile the
spectrum of genomic alterations acquired during tumorigenesis
and progression (Table 1 and Tables S1 and S2).
We initially focused on somatic point mutations. Several methods
of mutation calling have been developed, but agreement among the
various methods is poor (28); at the beginning of our studies, there
was no independent evaluation of which method had optimal
sensitivity and specificity. An added challenge was that available
methods were developed to call mutations in human tumors, and
many had parameters (e.g., background mutation rate) that were
optimized for human samples. Therefore, we created a controlled
dataset to assess the performance of our variant-calling pipeline in a
murine background by simulating mixtures of tumor and normal
DNA using exon capture of mixtures of germ-line DNA from dif-
ferent inbred mouse strains (Fig. S1A).
As a first step, we generated exon-capture sequencing libraries
with tail DNA from inbred C57BL/6 and 129S1/SvImJ mice. To
simulate tumor subclonal heterogeneity and contamination with
infiltrating nontumor stromal cells, we serially diluted the 129S1/
SvImJ library (mimicking “tumor DNA”) into the C57BL/6 library
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Fig. 1. Diagrams illustrating the mouse models of mutant Kras-, mutant
EGFR-, and MYC-induced lung adenocarcinoma used in whole-exome se-
quencing. (A and B) Kras models. (A) Mice carrying conditional KrasLSL-G12D
and p53flox/flox alleles develop lung adenocarcinomas upon administration of
lenti-cre. Cell lines were generated from primary and metastatic lung tu-
mors. Tumors and cell lines were collected for exome sequencing. (B) Mice
carrying KrasLA2-G12D;p53−/− form lung adenocarcinomas spontaneously.
Primary tumors were collected for exome sequencing. (C) EGFR model:
Bitransgenic CCSP-rtTA;TetO-EGFRL858R mice were treated with doxycycline
at weaning to induce transgene expression (10). Tumors were collected from
untreated tumor-bearing mice, or mice were treated with erlotinib as de-
scribed until the appearance of resistant tumors (12). Untreated and erlotinib-
resistant lung tumors were collected and used for exome sequencing. (D) MYC
model: Bitransgenic CCSP-rtTA;TetO-MYC mice were treated with doxycycline
at weaning to induce transgene expression. Overexpression of MYC in type II
pneumocyte leads to the development of lung adenocarcinomas that were
collected for whole-exome sequencing (26).
Table 1. Lung adenocarcinoma GEMMs used for the sequencing study
Initiating driver Cell line or tumor Genotype Tumor Induction Treatment No. studied
Kras-G12D Cell line Kras-LSL-G12D;Trp53 FL/FL Lenti-Cre n/a 15
Kras-G12D Tumor Kras-LSL-G12D;Trp53 FL/FL Lenti-Cre n/a 9
Kras-G12D Tumor Kras-LSL-G12D Lenti-Cre n/a 8
Kras-G12D Tumor Kras-LA2; Trp53−/− Spontaneous recombination n/a 4
EGFR-L858R Tumor CCSP-rtTA;tetO::EGFR-L858R Doxycycline None 10
EGFR-L858R Tumor CCSP-rtTA;tetO::EGFR-L858R Doxycycline Erlotinib-resistant 6
MYC Tumor CCSP-rtTA;tetO::MYC Doxycycline n/a 5
GEMMs are grouped by initiating driver event, and columns show the tumor type (studied as a cell line or primary tumor tissue), genotype of animals,
method of cancer gene induction, and number of samples from each model included in the study. Additional details on the models are provided in SI
Appendix and Fig. S1. n/a, not applicable.
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(mimicking “normal DNA”) (Fig. S1A). The starting libraries and
mixtures were sequenced to a median average depth of 132×
(range from 92× to 205×). Somatic mutations were identified by using
both muTect (Version 1.1.4) and a somatic mutation caller developed
by our group (hereafter referred to as the HaJaVa caller) based on
the GATK UnifiedGenotyper with filtering to call somatic events (as
described in detail in Methods and SI Appendix) (29). By using this
approach, individual germ-line polymorphisms can be traced through
the serially diluted libraries, mimicking somatic variant detection in
tumors. This dataset was used to estimate the false-positive and false-
negative rates at decreasing allelic fraction.
At the indicated depth of coverage, muTect was highly sensi-
tive, particularly at low allelic fractions that might be found in
samples with a low fraction of tumor cells or as a result of subclonal
mutational events, but it exhibited a higher false-positive rate. In
contrast, the HaJaVa caller exhibited a higher true-positive rate,
but also a higher false-negative rate at low allelic fraction (Fig. S1
B–D, SI Appendix, and Table S3). We found that the intersection
of the two callers exhibited a lower false-positive rate than either
caller alone, reducing missed calls by ∼50%, with a minimal in-
crease in the false-negative rate. Evidence that aggregating calls
from multiple methods improves performance was also recently
described, supporting this approach (24, 30). Therefore, we used
the intersection of the HaJaVa and muTect calling algorithms to
identify somatic mutations and to compare datasets among the
EGFR, MYC, and Kras models.
Kras-Driven Models of Lung Adenocarcinoma. We generated DNA
from a large panel of tumors and tumor-derived cell lines from
KrasLSL-G12D-based mouse models for whole-exome sequencing
(Table 1). We sequenced DNA from 15 tumor cell lines derived from
tumor-bearing KrasLSL-G12D;Trp53fl/fl mice, following the lentivirus-
based delivery of cre recombinase (Fig. 1) (31). In nine cases, we also
sequenced DNA from the parental tumor from which the cell lines
were derived. In addition, to determine whether expression of cre
recombinase generated unexpected mutations, we sequenced
DNA from four tumors arising in the KrasLA2-G12D;Trp53−/−
model, in which spontaneous recombination at the Kras locus,
rather than cre-induced recombination, initiated tumorigenesis
(32). Finally, to assess the potential impact of p53 loss on mu-
tation frequency, we sequenced DNA from eight tumors initi-
ated in KrasLSL-G12D;Trp53WTanimals.
We observed a median nonsynonymous mutation frequency of
0.07 per Mb (including missense and nonsense mutations and
mutations affecting splicing signals; range 0.00–0.46; Fig. 2A) in
Kras-driven tumors (cell lines are excluded from this analysis;
see below). Interestingly, we did not observe statistically differ-
ent mutation frequencies between Trp53-null (0.07 mutations
per Mb) and wild-type (0.06 mutations per Mb; P = 0.60; Fig.
2B) tumors. Tumors initiated in the KrasLSL-G12D;Trp53fl/fl model
harbored numbers of mutations (0.09 mutations per Mb) similar
to those in the KrasLA2-G12D;Trp53−/− model (0.03 mutations per
Mb; P = 0.1; Fig. 2C). With the KrasLSL-G12D;Trp53fl/fl model, we
observed a statistically significant increase in the mutation fre-
quency in tumor-derived cell lines (0.25 mutations per Mb)
compared with primary tumor specimens (0.07 mutations per Mb;
P = 0.001; Fig. 2D). This result may reflect the presence of subclonal
mutations present in the genomes of cell line-founder clones that
would be expected to be enriched during the generation of tumor cell
lines; however, we cannot exclude the possibility that new mutations
arose de novo during generation of the cell lines.
If the higher mutation frequency observed in tumor cell lines
compared with dissected tumor specimen reflects expansion of a
tumor subclone during generation of the cell line rather than ac-
quisition of new mutations in vitro, the mutational burden of
single cell genomes within tumors must be similar to the tumor
cell lines. Therefore, the lower frequency of mutations observed
in tumors compared with cell lines suggests that many of the
mutations observed in cell lines existed in tumor subclones occu-
pying a minority of the tumor mass, below the resolution of de-
tection by exome sequencing. In addition, not all mutations
observed in dissected tumor specimens, including events with
relatively high allelic fraction (>25%), were detected in the tumor
cell lines derived from the tumor. Together, these results suggest a
degree of clonal heterogeneity within the tumors, which is con-
sistent with enrichment of subsets of shared mutations between
cell lines and tumor specimens and, conversely, absence of other
mutations detected in the tumors, but not cell lines. The absence
of clonal enrichment of these events within the tumor dissected
from the animal further predicts that the majority of mutations
observed only in the cell lines are passenger events that do not
endow selective advantage in autochthonous tumors, at least
within the number of cell divisions these tumors have undergone
by the time of animal necropsy. We also did not observe a pre-
dilection for specific base transitions or transversions in the tu-
mors or cell lines (Fig. S2).
We compared these datasets to available sequencing data from
human lung adenocarcinoma (Fig. 2E). We observed significantly
fewer nonsynonymous mutations in GEMMmodels than in either
smoker- or nonsmoker-associated human lung adenocarcinomas
(Kras GEMM, 0.07 mutations per Mb; nonsmoker-associated,
1.97 mutations per Mb; P < 0.0001; and smoker associated, 7.76
B
D
FE Kr
as
-LS
L
Kr
as
-LA
2
0.0
0.2
0.4
0.6
M
ut
at
io
ns
/M
b
C
Ce
ll L
ine
Tu
mo
r
0.0
0.2
0.4
0.6
M
ut
at
io
ns
/M
b
Un
tre
ate
d
Re
sis
tan
t
0.0
0.2
0.4
0.6
M
ut
at
io
ns
/M
b
p5
3 W
T
p5
3 N
UL
L
0.0
0.2
0.4
0.6
M
ut
at
io
ns
/M
b
Kr
as
EG
FR MY
C
0.0
0.2
0.4
0.6
M
ut
at
io
ns
/M
b
A
Kr
as
Hu
ma
n N
on
Sm
ok
er
Hu
ma
n S
mo
ke
r
0.01
0.10
1
10
100
M
ut
at
io
ns
/M
b
Fig. 2. Low mutational burden in GEMM models of lung cancer. (A) Dot
plots showing the nonsynonymous mutation frequency observed from whole-
exome sequencing datasets in murine LUADs induced by oncogenic Kras
(tumors from either the LA2 or LSL models; tumor-derived cell lines are ex-
cluded; see below), EGFR, or overexpression of MYC. (B) Trp53 null vs. wild-
type tumors. (C) KrasLA2-G12D;p53−/− vs. KrasLSL-G12D;Trp53fl/fl tumors.
(D) KrasLSL-G12D;Trp53fl/fl tumors vs. tumor-derived cell lines. (E ) Comparison
of KrasG12D-induced tumors to human lung adenocarcinomas (ref. 4) from
smoking and nonsmoking patients, shown in log scale. (F) Untreated vs.
drug-resistant EGFRL858R-induced LUADs. Mean and SEM are shown.
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mutations per Mb). Even assuming that the true cancer cell mu-
tation frequency reflects that observed in cell lines (0.25 mutations
per Mb), the mutational burden in the mouse models remains
significantly lower than that observed in human lung cancers. The
relatively low number of mutations observed in murine tumors
might reflect a lower number of cell divisions that the cells of
origin and tumors have undergone relative to human cancers, a
difference in mutation rate per cell division, or a combination of
these. We cannot discriminate between these possibilities with
available datasets because the number of cell divisions in murine
tumors was neither quantified nor estimated in this study.
We identified independent recurrent mutations in a number of
genes, including C5ar1, Dnahc5, Nyap2, Pcdh15, Pclo, Rngtt, Stil,
Tenm4, and Xirp2. Seven genes (Csmd1, Hmcn1, Kmt2c, Pcdh15,
Pclo, Ttn, and Xirp2) mutated in the mouse KrasG12D cell lines
and tumors were also recurrently mutated in >15% of samples in
human lung adenocarcinomas (LUADs), as reported by The
Cancer Genome Atlas (TCGA). Therefore, Pcdh15, Pclo, Ttn,
and Xirp2 were recurrently mutated in both the mouse model
and human lung adenocarcinoma (4) (Fig. 3, denoted with an
asterisk). However, mutations in PCDH15, PCLO, TTN, and
XIRP2 were evenly distributed across the coding sequence of
these genes, rather than clustered as hot spot events in human
cancers (www.cbioportal.org). Therefore, we refrain from spec-
ulating that these mutations act as driver alterations, considering
ambiguous evidence for a functional role of each of these genes
in human cancer.
As one example, Xirp2 encodes an actin-binding protein
implicated in the maintenance of inner ear hair cell stereocilia
and cardiac myocyte remodeling. Xirp2 was mutated in two
independent primary tumors and one related primary tumor-
metastasis cell line pair, the latter of which harbored the same
Xirp2 mutation within a highly conserved region of the Xin
actin binding repeats (33–35). Xirp2 has no known role in
cancer, and despite 21% of human lung adenocarcinomas in
the TCGA study harboring mutations in XIRP2, it was not
considered a “significantly mutated” gene (4). Review of RNA-
sequencing data from the TCGA study revealed very low ex-
pression of XIRP2 mRNA in human lung adenocarcinoma,
suggesting that mutations in XIRP2 may be passenger events,
despite their high frequency. Furthermore, XIRP2 is primarily
expressed in muscle tissues, and it is not known to be expressed
in lung tissue (36). In addition, XIRP2 mutations observed in
human lung adenocarcinoma are distributed across the entire
coding sequence and the human and mouse XIRP2 genes are
large, encoding peptides >3,500 amino acids in length. Theo-
retically, it is possible that XIRP2 mutations might have been
selected at an early stage of tumorigenesis, but may not have
been advantageous during outgrowth of the dominant tumor
subclone before clinical detection. However, the preponder-
ance of evidence suggests that mutations in Xirp2 are pas-
senger alterations, although the mechanism behind frequent
mutation of this gene in human and mouse cancers remains
undefined.
We also observed recurrent mutation of Pclo, which has been
shown to be important for axonal guidance during central ner-
vous system development. PCLO, which was mutated in 21% of
lung adenocarcinomas in the TCGA study, was also recently
identified as a recurrently mutated gene in liver cancers
exhibiting a biliary phenotype (37). Knockdown of PCLO RNA
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Fig. 3. Mutational landscape of oncogene-induced mouse lung adenocarcinomas. Schematic diagram of genes mutated in the mouse lung adenocarcinomas
and cell lines is shown. (Top) Kras-, EGFR-, and MYC-induced tumors are indicated and shaded in red, blue, and purple, respectively. The Trp53 status is
indicated (black, null; gray, heterozygous). (Middle) Genes mutated in two or more samples are indicated. (Bottom) Genes mutated in the murine tumors that
are also mutated in >15% of lung adenocarcinomas analyzed in the TCGA. Note that Csmd1, Hmcn1, and Kml2c were not recurrently mutated in murine
tumor, whereas asterisk-indicated genes were recurrently mutated in human and murine tumors. Erlotinib-resistant tumors are indicated. Stars are used to
highlight tumors harboring an EGFR T790M mutation (by conventional Sanger sequencing).
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in human liver cancer cells led to an increase in cell migration.
We identified two mutations in Pclo, a nonsense mutation
(E577X) and E1850K; the latter resides in a conserved region
of the protein with unknown function. Further investigation of
the role of Pclo alterations, especially in the context of Kras
mutations, seems warranted.
Manual review of mutations occurring in a single tumor
revealed mutations in several genes encoding regulators of tran-
scription, including several factors involved in chromatin modifi-
cation and regulation. Among these are mutations in Brd4
(H965P, within a proline-rich domain of unknown function), Chd7
(a nonsense mutation, R977X), Chd8 (H2198R), Mll3 (T1798S),
Mlxip (V453G), Smarcb1(M27R), Smyd4 (H769R), and Tet1
(C1784X) (Table S4). None of these specific mutations has been
identified in human cancers. Therefore, it is difficult to determine
whether any of these mutations represent driver events. However,
mutations in many epigenetic regulators in human tumors are not
clustered into hot spots, so it is premature to conclude that these
represent passenger mutations in the mouse model.
EGFR-Driven Model of Lung Adenocarcinoma. Tetracycline-inducible
expression of the EGFRL858R mutant in the lung epithelium
of transgenic mice leads to the formation of lung adenocarci-
nomas with bronchioalveolar carcinoma features that are sen-
sitive to treatment with EGFR tyrosine kinase inhibitors (TKIs)
like erlotinib (10). Long-term intermittent dosing of the mice
with erlotinib leads to the emergence of drug-resistant tumors
that harbor some of the molecular features of TKI-resistant
human tumors, including a secondary mutation in EGFR,
EGFRT790M (12). To determine the mutational load of these
tumors, compared with tumors initiated by alternate onco-
genes, and to seek genetic differences between untreated and
erlotinib-resistant tumors, we performed whole-exome se-
quencing of DNA from 10 TKI-naïve and 6 erlotinib-resistant
EGFRL858R-induced mouse lung adenocarcinomas. We ob-
served a lower mutational burden in EGFR mutant lung ade-
nocarcinomas compared with Kras-driven tumors (0.02 vs. 0.07
mutations per Mb, P = 0.002; Fig. 2A). Erlotinib-resistant tu-
mors exhibited no difference in mutation frequency compared
with untreated EGFR mutant tumors (0.02 vs. 0.02, P = 0.49;
Fig. 2F). The mutational signature present in the EGFRL858R
-induced lung adenocarcinomas exhibits a preponderance of
C > T transitions, consistent with findings in EGFR mutant
human lung adenocarcinomas and all adenocarcinomas from
never-smokers (4) (Fig. S2). Interestingly, this result was sig-
nificantly different from the signature observed in the Kras
mutant tumors (P = 0.0008), although the mechanistic basis for
this observation remains to be determined.
Recurrent mutations in the tumors were found in Kras (n = 4
total; 2 G12V and 2 Q61R) and Ube3b (n = 2). We previously
described an oncogenic Kras mutation in an erlotinib-resistant
murine tumor; however, such mutations have not been described
in patients (12). Interestingly, two of the Kras mutations ob-
served here (with nonreference allele fractions of 0.38–0.55)
were found in the 10 tumors not treated with TKIs, suggesting
that these mutations can arise during tumor development inde-
pendent of treatment. A recent report shows that coexpression
of mutant EGFR and KRAS in the same human lung tumor cells
can be toxic (38). It is possible that detection of mutations in
both oncogenes in some untreated tumors indicates that ex-
pression of one of the oncogenes has been down-regulated in at
least some tumor cells; in other tumors with both mutations,
inhibition of the EGFR kinase activity with a TKI may have been
a permissive feature.
Ube3b, an E3 ubiquitin ligase, was mutated in two individual
tumors from a single untreated mouse. The same variant was
found in both tumors, suggesting that the two tumors are clonally
related. According to TCGA reports, Ube3b is altered in 4% of
human LUADs; however, there is no indication at this point of
a functional relationship between EGFR mutations and alter-
ations in Ube3b.
Because a major mechanism of resistance to EGFR inhibitors
is a secondary mutation in EGFR (EGFRT790M), we examined
the whole-exome sequencing data to determine whether we
could detect reads corresponding to human EGFR (because the
transgene encodes human EGFR). Indeed, we unequivocally
detected the EGFRT790Mmutation in one erlotinib-resistant tumor
that we had previously shown to harbor this mutation. However,
we cannot exclude inadequate depth of sequencing of the human
EGFR transgene as an explanation of our failure to identify other
cases of secondary T790M mutations of EGFR in these tumors,
especially because the exon capture probes did not target human
EGFR sequences.
MYC Model of Lung Adenocarcinoma. The low mutation burden
observed in the Kras- and EGFR-induced lung tumors
prompted us to hypothesize that tumors induced by strong
oncogenic lung drivers might have a lower mutation burden
than tumors induced by a less potent lung oncogene. We
therefore performed whole-exome sequencing of DNA from
five lung adenocarcinomas that arose in a mouse model initi-
ated by overexpression of wild-type human MYC, which has
been shown to be a less potent oncogene than mutant KRAS or
EGFR in the murine lung (26).MYC-induced tumors also exhibited
a low mutation frequency, comparable with that observed in Kras-
induced mouse lung adenocarcinomas (0.14 vs. 0.07 mutations
per Mb, P = 0.57; Fig. 2A). The mutations found in the MYC-
induced tumors included oncogenic Krasmutations in three of five
tumors and an oncogenic mutation in Fgfr2 (Fgfr2 K659M) in one
tumor. The Kras and Fgfr2 mutations were independently vali-
dated by using Sanger sequencing. Mutations at this residue in
FGFR2 have been shown to activate the intrinsic protein–tyrosine
kinase and to cooperate with MYC in tumorigenesis (39, 40). The
identification of known cancer driver mutations in four of five
MYC-driven tumors is consistent with the suggestion that MYC
acts as a less potent tumor initiator that mutant Kras or EGFR in
the murine lung.
Acquired Whole-Chromosome Copy Number Changes Are Common in
Mouse Lung Adenocarcinomas. Given the low point-mutation burden
observed in the mouse tumors in our GEMM models, we asked
whether the tumors harbored alterations in chromosomal or
subchromosomal copy numbers. To examine somatic changes in
DNA copy number in the GEMM tumors, we analyzed the datasets
from whole-exome sequencing using validated computational
methods (41, 42). We first examined the Trp53 locus, which was
anticipated to be deleted in the tumors when Cre recombinase was
expressed to initiate tumorigenesis (25). We detected deletion
of exons 2–10 in all tumor cell lines derived from those animals,
suggesting that the method based on sequence data accurately
identified small regions of deletion (Fig. S3).
When these methods were applied to the complete set of
exome-sequencing data, we primarily detected putative whole
chromosome gains and losses in the murine lung adenocarci-
nomas (Fig. 4), consistent with prior studies of cancers arising
in GEMMs (16, 17). Manual review of putative focal amplifi-
cations and deletions revealed that many likely resulted from ar-
tifacts or biases in the dataset. In particular, a set of breakpoints
exhibiting the same start and stop positions in several tumors
matched to the same normal sample (i.e., these tumors were
isolated from the same animal). These events likely represented
artifacts of variable coverage during sequencing of normal (tail)
DNA. Another set of events consisted of regions with nearly
balanced amplifications and deletions, which overlapped anno-
tated duplication regions. These events likely represented copy
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number polymorphisms, some of which could be germ-line events
(Table S5).
Although the models used in this study all produced one his-
tological tumor type, lung adenocarcinoma, the tumors that de-
velop in each GEMM showed a distinct pattern of recurrent
DNA copy number gain or loss (Fig. 4 A–C and Table S5). Kras-
driven tumors and cell lines harbored recurrent gain of Chr6,
consistent with prior studies of Kras-induced lung tumors (16, 17,
24, 43). In addition to extra copies of Chr6, we observed recur-
rent whole-chromosome amplification of Chr2, Chr15, and
Chr19 (in ≥20% of samples) and whole-chromosome loss of
Chr9 and Chr14 (Table S5). These alterations have been ob-
served in murine tumors by other investigators using different
methods for copy-number determination, lending additional
confidence in our exon capture-based copy number analysis (16,
17, 24). Because Chr6 carries the Kras locus, we determined the
allelic fraction with the G12D mutation; this analysis suggested
that the chromosome with the engineered G12D mutant, not the
chromosome with the wild-type allele, was responsible for the
gain in chromosome number (Fig. S4). Similarly, the proto-
oncogene Myc is on Chr15, and gain of copies of Chr15 is the
second most frequent whole-chromosome alteration observed in
this model and is consistent with previous work suggesting that
Myc function may be necessary for tumor maintenance in Kras-
driven GEMMs (44).
Recurrent whole-chromosome DNA copy number changes
appeared to be less frequent in the EGFR-driven GEMMs (Fig. 4
and Table S6), and a different pattern of changes was observed.
For unexplained reasons, an increased number of copies of Chr12
was the most recurrent alteration. It is possible that the unmapped
TetO–EGFR transgene is integrated in Chr12; gain in copy num-
ber might then increase signaling from the EGFR oncogene.
We did not observe an anticorrelation between the frequency of
point mutations and the fraction of the genome affected by DNA
copy number alterations, as previously described (24). This finding
might in part be due to the overall low mutational burden ob-
served in these tumors, which is approximately an order of mag-
nitude lower than that observed in carcinogen-induced models (mean
of 185 mutations in urethane-induced and 728 in methylnitrosourea-
induced tumors) (24). Therefore, it is possible that, when
higher mutation loads are present, there is less selection for
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large-scale DNA copy number alterations across the genome in
these models.
Discussion
Recent improvements in DNA-sequencing technologies have
spurred the genomic characterization of many types of human
cancers, including lung adenocarcinomas. These datasets have
revealed much information about the mutational profiles of this
cancer and identified several novel putative oncogenes and tu-
mor suppressors. However, unraveling the complexity of these
datasets and distinguishing driver and passenger mutations remain
significant challenges, particularly in highly mutated genomes such
as smoking-associated lung adenocarcinoma. In contrast, in this
work, we have observed a very low mutation burden in EGFR-,
Kras-, and MYC-driven GEMM tumors, regardless of tumor ge-
notype. The low mutation burden in the murine tumors is con-
sistent with prior studies in other GEMMs (24). Together, these
findings suggest that the number of mutations necessary for the
development and progression of invasive lung adenocarcinomas in
mice is small. To conduct these analyses, we developed a pipeline
for somatic mutation calling in mouse exome datasets that was
adjusted to minimize the calling of false positives. This performance
was achieved by testing two different SNP callers on a set of germline
polymorphisms that distinguish the inbred mouse strains C57BL/6
and 129sV/J. Through this analysis, we found that the highest sen-
sitivity and lowest false-positive rates were observed when the in-
tersection of both callers was used in the analysis, consistent with
recent findings in the literature (30).
We detected recurrent whole-chromosome gains and losses
in the EGFR- and Kras-driven models. These observations raise
the question of whether copy number alterations are contrib-
uting to tumorigenesis in these models. Considering that we
observed recurrent Chr6 amplification—which encodes the
engineered KrasLSL-G12D allele as well as several components of the
MAPK signaling pathway—in Kras-driven models, we speculate
that cooperating oncogenes and/or tumor suppressors located in the
regions of whole-chromosome gain or loss indeed contribute to
tumor progression. However, the identity of the driver events in the
amplified and deleted regions remains to be determined. These
observations suggest that amplification of the signal from the initi-
ating oncogene may be the most important somatic event in these
models to drive tumor progression (43).
Previous work also described changes in gene expression
during tumor progression, suggesting that epigenetic alterations
contribute to progression in these models (13). The detection of
several mutations in transcriptional regulators and chromatin-
remodeling factors in our models (Fig. 3) is consistent with these
findings, although we have not determined directly whether any
of the observed mutations accelerate tumor progression or lead
to specific changes in chromatin in these models.
We found evidence for clonal selection during the emergence
of drug resistance and during the generation of tumor-derived
cell lines. Tumors harvested from mice with EGFR-mutant lung
cancer harbored oncogenic lesions known to confer primary or
acquired resistance to TKIs (for example, Krasmutations and the
EGFR T790M mutation, respectively). In addition, in the Kras-
driven model, tumor cell lines harbored a higher mutation load
compared with the parental tumors, suggesting clonal selection
during outgrowth of cell lines.
Despite the low frequency of observed somatic events in the
GEMM tumors, each model exhibited distinct features. In con-
trast to the Kras and EGFR models, which harbored few muta-
tions known to act as cancer drivers, four of five MYC-induced
tumors harbored oncogenic mutations in Kras or Fgfr2. The ac-
quisition of potent driver mutations in these tumors suggests
that MYC overexpression sensitizes cells to transformation by
cooperating with spontaneous Kras or Fgfr somatic mutations. In
contrast, even in the absence of Trp53, Kras-driven tumors did
not acquire mutations in known tumor suppressors or oncogenes.
This finding highlights the potency of this oncogene and strongly
suggests that the initiating genetically engineered allele is a critical
determinant of acquired events in these models.
The fact that tumor-initiating overexpression of MYC required
additional spontaneous mutations in Kras or Fgfr is a strong tes-
tament to the centrality of MAPK signaling in lung adenocarci-
noma. In addition, the fact that Kras-mutant models acquired few
other recurrent drivers further suggests that initiating MAPK ac-
tivation is sufficient for tumorigenesis. The most frequently ob-
served somatic alteration in Kras-mutant tumors was amplification
of Chr6, which encodes the initiating oncogene and additional
signaling components of the MAPK pathway. Although additional
acquired driver alterations, or independent tumor-initiating events
(e.g., MYC expression), may cooperate to drive tumor develop-
ment, these data underscore the importance of maintaining sig-
naling through the MAPK pathway in lung adenocarcinoma.
The overall nonsynonymous mutation burden in human lung
adenocarcinomas is 6.86 mutations per Mb (lung TCGA). This
frequency is ∼50-fold higher than the median mutation burden
observed in any of the mouse lung adenocarcinomas studied
here. In part, this finding is likely to reflect the lack of carcinogen
exposure. However, the mutation frequency in never-smokers
(1.97 mutations per Mb) remains >10-fold higher than that ob-
served in our lung cancer models (4). The rapid development of
tumors in mice may also contribute to the reduced complexity of
the cancer genome in these models compared with human lung
adenocarcinoma. As previously described, the copy number pro-
files of mouse tumors were generally characterized by large-scale
whole-chromosome gains or losses (14, 15, 17, 18). In contrast,
human tumors exhibited both large-scale and focal amplifications
and deletions, perhaps also reflecting differences in carcinogen
exposures in tumors in the two species (45).
Our findings have important implications for the optimal use
and further development of GEMMs, particularly considering the
ease with which these modifications can be generated by using new
genome-editing methods (46–48). Although we have not se-
quenced to the extreme depth necessary to identify mutations in
very small subpopulations of tumor cells, the genomic profile of
these models appears to be much less complex than most human
cancers. The genomic complexity of lung cancer is at the heart of
drug resistance and appears to be an important determinant of the
response to immune checkpoint inhibitors (49).
We previously reported that tumors in the KrasLSL-G12D;
Trp53fl/fl model exhibit very modest immune cell infiltrates (50).
This finding is consistent with very few neoantigens generated as a
result of the very low number of somatic mutations that arise
during tumor development as we describe here. However, ex-
pression of a strong T-cell antigen in the model induces a potent
T-cell response, which is subsequently suppressed at later stages of
tumor progression (50). Therefore, it is important to consider the
low mutational burden exhibited in tumors in these GEMMs when
designing therapeutic studies or studies of drug resistance. At the
same time, the uniformity of the programmed somatic mutations
and low acquired mutation frequency observed in tumors in these
models are important experimental strengths, making the
models well suited to reproducible mechanistic studies and ge-
netic screening. Efforts to model genomic complexity in GEMMs,
by using mutagens, transposons, or engineered loss of DNA repair
pathways, are approaches to further optimize GEMMs for studies
of sensitivity and resistance to therapies and could identify new
drivers of progression and metastasis that cooperate with the
initiating engineered mutations.
Methods
Mouse Models. All animal studies were performed under approved Institu-
tional Animal Care and Use Committee protocols at the Massachusetts In-
stitute of Technology and Memorial Sloan Kettering Cancer Center. Tumor
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induction was performed in KrasLSL-G12D;p53fl/fl and KrasLSL-G12D mice as
described with 2.5 × 104 lentivirus particles per animal (31). Tumors were
isolated and tumor-derived cell lines were generated as described (13).
Histological analysis was performed on a piece of each tumor to assess tumor
purity and histological subtype of lung cancer. Tumor-derived cell lines were
probed by Southern blotting using a radioactive probe to cre cDNA se-
quences to confirm a single viral integration and independent origin of
tumor cell lines as described (13). Tumors were induced in the TetO-EGFRL858R
and TetO-MYC models by feeding the mice doxycycline-impregnated food as
described (10).
Exome Sequencing. DNA was purified from tumor tissue and tumor cell lines
by using standard methods. Sonication of 2 μg of genomic DNA was
performed by using a Diagenode Bioruptor, and size selection was
performed by using dual selection using AMPure beads as described (51).
Exon capture was performed by using Roche SeqCap EZ all-exon mouse kits.
Postcapture libraries were sequenced on an Illumina HiSeq instrument.
Variant Calling. The pipeline to call somatic mutations was predominately
composed of standard programs that have been used in human tumor
analysis, with the addition of a custom caller that was optimized to reduce
false positives at the expense of some sensitivity to low-allele frequency
events. The final mutation list was the intersection of these two calling al-
gorithms in the hope that artifacts giving rise to false positives in one would
be filtered out by the other.
Raw sequence files were first preprocessed to remove the sequencing
adapters. Then, clipped reads weremapped to the standardmm9 genome for
the Kras model or to mm9+transGene (hEGFR or hMYC) hybrid genomes for
the EGFR and MYC models. BWA ALN (Version 0.5) was used to make maps.
The reads were marked with read groups and sorted, and then duplicates
were removed by using the PICARD toolkit. These initial bam files were
postprocessed by using the standard GATK packages; indel realignment was
followed by base quality recalibration. The postprocessed bam files were
then called by using two separate mutation callers: MuTect (Version 1.1.4) in
high-confidence mode and a custom caller built around the GATK Unified
Genotyper, with a set of filters to improve specificity. An intersection of
these calls were postfiltered for artifacts by removing any events that were
in a database of likely germ-line events (see SI Appendix for details). Ap-
proximately 50 somatic mutation calls were independently validated by PCR
and Sanger sequencing, which suggested very high (>95%) accuracy of the
calling method. The calls were annotated with Annovar, and a list of
“functional” mutations was created that contained missense, nonsense, and
splice-site mutations.
DNA Copy Number. Copy number was determined by first computing nor-
malized log ratios between tumors and matched normals. This analysis was
performed by taking the bam files from the mutation-calling pipeline and
computing the coverage for each exon target region using bedtools. The
raw coverage numbers for each tumor normal pair were normalized with a
robust regression method that normalized not only for total depth but also
for the local GC content around each target region using the loess function
from R. The log (base 2) ratio of T to N was computed from the normalized
coverage, and this was then segmented by using the circular binary seg-
mentation method of ref. 27. A postsegmentation normalization was then
used to center the diploid peak at logR = 0. To find segments that were
either amplified or deleted, we used the RAE algorithm (28), which com-
putes a sample-dependent soft threshold (sigmoid function) for each tumor/
normal pair based on the noise of that pair. This algorithm gives a value of
0–1 for both amplifications and deletions, which approximately indicates
fractional amount of each alteration. These values were then averaged over
all samples to give the fraction of each region that was amplified or deleted
in a given set of samples.
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